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The role of S-1 in the treatment of gastric cancer
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S-1 is a potent antitumour drug in gastric cancer. After years of disagreement about the utility of chemotherapy for advanced gastric
cancer, several studies have recently demonstrated the efficacy of S-1 in both the adjuvant and primary settings. In this Minireview, the
value of S-1 in the treatment of gastric cancer is discussed.
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S-1 is a novel oral anticancer drug composed of tegafur (FT), 5-
chloro-2, 4-dihydroxypyridine (gimestat [CDHP]), and oteracil
potassium (Oxo) in a molar ratio of 1:0.4:1. This agent was
designed to enhance the oral efficacy of FT, a prodrug of 5-
fluorouracil (5-FU). CDHP inhibits the activity of dihydropyrimi-
dine dehydrogenase (DPD), an enzyme that degrades 5-FU, with
about 180-fold more potency than uracil, thereby maintaining
prolonged blood and tumour 5-FU concentrations. Oxo is
distributed in the gastrointestinal tract at a high concentration
following oral administration, and it prevents phosphorylation (i.e.,
activation) of 5-FU by inhibiting the effect of orotate phosphor-
ibosyl transferase (OPRT). S-1 therefore has improved tumour-
selective toxicity compared to 5-FU alone due to the actions of
CDHP and Oxo as shown in Figure 1 (Shirasaka et al,1 9 9 6 ) .
Pharmacokinetic analyses have supported this potent antitu-
mour activity of S-1. In a rodent model, S-1 doses that were
equitoxic to UFT doses resulted in higher 5-FU levels, as revealed
by the following pharmacokinetic measurements: single-day area
under the curve (AUC0–24) of 5-FU in plasma (3.5-fold), AUC0–24
of 5-FU incorporated into tumour RNA (1.3-fold), and tumour
thymidylate synthase inhibition rate (B20%). In a clinical
pharmacology study in 12 patients that examined blood concen-
trations of 5-FU following twice-daily administration of S-1
40mgm
 2 after meals, 5-FU blood concentrations ranged from
60–200ngml
 1 (Hirata et al, 1999). These results suggested that
oral S-1 administration should result in a similar concentration of
5-FU as intravenous 5-FU administration, and should therefore
have equivalent antitumour activity.
Herein, the role of S-1 in the treatment of gastric cancer is
discussed, with particular emphasis on its use as postsurgical
adjuvant therapy.
PHASE II S-1 STUDIES
Two phase II studies were conducted to confirm the antitumour
activity of S-1 in gastric cancer patients. In the first study, 51
patients with advanced gastric cancer without previous chemo-
therapy were enroled, 50 of whom were included in the efficacy
and safety analyses (Sakata et al, 1998). S-1 was administered
orally two times daily for 28 days, followed by a 2-week rest. Doses
were assigned according to patient body surface area: o1.25m
2,
40mg; 1.25–1.5m
2, 50mg; and X1.5m
2, 60mg. The overall
response rate (ORR) was 44% (19 out of 43), with a 95%
confidence interval (CI) of 30–59%. The median survival time
(MST) in all patients was 207 days, with 1- and 2-year survival
rates of 36.0 and 14.0%, respectively. The second phase II study
(Koizumi et al, 2000) enroled 51 patients with advanced gastric
cancer. S-1 80mgm
 2 per day was administered orally two times
daily. A single course consisted of consecutive administration for
28 days followed by a 2-week rest; administration was repeated
over four courses. The ORR was 49% (25 out of 51), with a 95% CI
of 35.9–62.3%.
Adverse events were generally mild in both phase II studies. In
the first trial, grade 3 adverse reactions included anaemia in two
patients and leukopenia, neutropenia, and diarrhoea in one patient
each. No grade 4 or unexpected adverse events were observed
(Sakata et al, 1998). In the second trial, the overall incidence of
adverse events was 78% (40 out of 51 patients), while the incidence
of grade 3 and 4 events was 20% and included anaemia,
leukopenia, granulocytopenia, diarrhoea, malaise, and proteinuria
(Koizumi et al, 2000). No serious unexpected adverse events were
observed in either study.
PHASE III S-1 STUDIES
Based on the encouraging results of a phase I/II study that
evaluated S-1þDDP, Koizumi et al (2008) conducted a rando-
mised, controlled, open-label, parallel, multicenter phase III study
(SPIRITS trial) comparing S-1 alone with S-1þDDP. Patients with
advanced/recurrent gastric cancer who had not previously received
S-1 were randomised to receive either S-1 40mgm
 2 two times
daily for 28 days followed by a 2-week rest or S-1 40mgm
 2 two
times daily for 21 days followed by a 2-week restþintravenous
DDP (60mgm
 2) on day 8. Between March 2002 and November
2003, 305 patients were randomised, with 299 patients eligible for
safety and efficacy evaluation. The 2-year MST was 335.5 days
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significantly longer in the combination arm than in the S-1
monotherapy arm (P¼0.0366). The RR was also higher in the
combination therapy arm (54.0%) than in the S-1 arm (31.1%).
The study authors concluded that this regimen should be regarded
as one of the first-line standard treatments for advanced/recurrent
gastric cancer.
Imamura et al (2008) conducted a multicenter, randomised
phase III trial comparing irinotecan (CPT-11)þS-1 (IRIS) to S-1
alone in advanced gastric cancer patients. Patients were rando-
mised to either S-1 40mgm
 2 two times daily for 28 days followed
by a 14-day rest or S-1 40mgm
 2 two times daily for 21
daysþCPT-11 80mgm
 2 on days 1 and 15 followed by a 2-week
rest. An interim analysis revealed an ORR of 26.9% for the
S-1 monotherapy arm and 41.5% for the IRIS arm (P¼0.035),
however IRIS didn’t show statistically significant superiority to S-1
alone in OS.
The combination of docetaxel and S-1 has been evaluated in two
phase II studies. In one study, Yoshida et al (2006) assessed the
efficacy and toxicity of docetaxel and S-1 for patients with
advanced/recurrent gastric cancer. Patients received intravenous
docetaxel 40mgm
 2 on day 1 and S-1 40mgm
 2 two times daily
for 14 days followed by a 1-week rest. The ORR was 56.3% (95%
CI, 38–66%). The MST was 14.3 months, and median time to
tumour progression was 7.3 months. No grade 4 nonhaematologic
toxicities were reported, and all treatment-related toxicities were
resolved. In the second phase II study (Yamaguchi et al, 2006),
treatment consisted of intravenous docetaxel 50mgm
 2 on day 1
and S-1 40mgm
 2 two times daily for 14 days, followed by a 2-
week rest. The maximum tolerated dose of docetaxel was
determined to be 50mgm
 2, and the recommended dose was
reduced to 40mgm
 2. In the 46 patients who received treatment,
the ORR and estimated median OS were 46% (95% CI, 31–61%)
and 14.0 months, respectively. The most common grade 3 of 4
toxicity was neutropenia, which was predictable and manageable.
These two phase II studies indicated that this regimen results in
extended survival despite a modest ORR, and that toxicity
is manageable. A phase III study (JACCRO GC-03/START trial)
is currently underway to compare S-1 monotherapy with
S-1þdocetaxel 40mgm
 2 in Japanese and Korean patients
with inoperable advanced or recurrent gastric cancer.
THE N-SAS-GC TRIAL: USEFULNESS OF UFT AS
ADJUVANT THERAPY AFTER GASTRIC SURGERY
UFT is the immediate predecessor of S-1. When this compound is
administered to patients, the degradation of tegafur is competi-
tively inhibited by uracil, a substrate of DPD, in a reversible
manner. Nakajima et al (2007) evaluated the survival benefit of
adjuvant UFT administration following curative resection of
advanced gastric cancer in which the tumour depth of invasion
is limited within the subserosal layer and the degree of lymph node
metastasis corresponds to N1-2 according to the Japanese
Classification of Gastric Carcinoma. Eligibility criteria included
curative gastrectomy with D2 or greater lymph node dissection,
ECOG performance status (PS) 0–2, and no prior chemotherapy.
Patients were randomised in a 1:1 ratio to surgery plus adjuvant
chemotherapy or surgery alone. The UFT arm consisted of oral
UFT 360mgm
 2 per day for 5 days with a 2-day rest, beginning 6
weeks after surgery and ending 16 months after surgery. The
primary end point was OS, and relapse-free survival was a
secondary end point. Although enrolment of 244 patients in each
arm was initially planned, the study was closed after accrual of 190
patients, due to slow recruitment primarily caused by the wide
introduction of S-1 into clinics. The planned second interim
analysis was conducted in November 2004 after a median follow-
up of 3.8 years (3 years after registration was closed). A total of 188
patients were randomised to the UFT arm (n¼93) or the surgery-
alone arm (n¼95). Patients in the UFT arm experienced
significantly longer 5-year OS (86 vs 73%, P¼0.017, hazard ratio
[HR]¼0.48) and 5-year relapse-free survival (85 vs 68%, P¼0.005,
HR¼0.44) compared to patients in the surgery-alone arm.
Although the planned sample size was not achieved, the results
of this study suggested that adjuvant oral fluoropyrimidine
monotherapy can provide a definitive survival benefit in advanced
gastric cancer patients, with minimal adverse effects.
ADJUVANT CHEMOTHERAPY FOLLOWING CURA-
TIVE RESECTION OF GASTRIC CANCER: THE ACTS-
GC TRIAL
Prior to the use of S-1 in postgastrectomised patients, Kinoshita
et al (2004) conducted a feasibility study of S-1 in curatively
resected gastric cancer patients. S-1 80–120mgday
 1 was
administered for 4 weeks followed by a 2-week rest, for a total of
eight courses. From November 1999 to October 2000, 41 patients
from 11 institutions were enroled, and 35 patients were eligible for
safety and efficacy analyses. Among the 28 patients who did not
experience recurrence, the planned eight courses of S-1 were
administered to 17 patients (60.7%). Four patients refused
continuous S-1 administration due to subjective symptoms, such
as anorexia, during the first course. Although adverse events
including neutropenia, leukopenia, elevated total bilirubin, anorexia,
general fatigue, diarrhoea, nausea, and stomatitis were observed in
450% patients, no grade 4 adverse events occurred. Thus,
postoperative administration of S-1 for 1 year appears to be
feasible as adjuvant chemotherapy for gastric cancer.
On the basis of this study, Sakuramoto et al (2007) initiated the
ACTS-GC trial, which evaluated single-agent S-1 as adjuvant
chemotherapy for Japanese patients with stage II/III (Japanese
Classification of Gastric Carcinoma) gastric cancer following
curative D2 dissection. Inclusion criteria included R0 resection,
pathological stage II/III (excluding T1 cases), age 20–80 years, no
prior adjuvant treatment, and adequate organ function. Patients
were randomly assigned to receive surgery plus S-1 or surgery
alone. S-1 80mgm
 2 per day was administered for 4 weeks
followed by a 2-week rest beginning within 45 days of surgery and
ending 1 year after surgery. The primary end point was OS. Two
interim analyses were planned at 1 and 3 years after enrolment was
completed. Between October 2001 and December 2004, 1059
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Figure 1 The mode of action of S-1. S-1 is composed of tegafur (FT),
5-chloro-2, 4-dihydroxypyridine (gimestat [CDHP]), and oteracil potassium
(Oxo) in a molar ratio of 1:0.4:1 to enhance the oral efficacy of FT, a
prodrug of 5-fluorouracil (5-FU). CDHP inhibits the activity of dihydro-
pyrimidine dehydrogenase (DPD), an enzyme that degrades 5-FU, with
about 180-fold more potency than uracil. Oxo is distributed in the
gastrointestinal tract at a high concentration following oral administration,
and it prevents phosphorylation (i.e., activation) of 5-FU by inhibiting the
effect of orotate phosphoribosyl transferase (OPRT).
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arm and 530 randomised to the surgery-alone arm; no significant
differences in baseline characteristics existed between the two
groups. When the first interim analysis was conducted in June
2006 using the survival data acquired through December 2005, the
HR of death for S-1 to surgery alone was 0.57 (95% CI, 0.40–0.81;
P¼0.0016). On the basis of these results, the data and safety
monitoring committee recommended halting this trial. When the
final analysis was conducted in September 2006, using data
through June 2006, 3-year OS was 80.5% (95% CI, 76.6–84.4%) for
S-1 patients and 70.1% (95% CI, 65.5–74.6%) for patients who
received surgery alone. The HR of death for S-1 was 0.68 (95% CI,
0.52–0.87; P¼0.0024). A total of 65.8% patients completed S-1
therapy. The results of this trial demonstrated that adjuvant
chemotherapy with S-1 for stage II/III gastric cancer is feasible and
effective, and suggested that adjuvant S-1 should be adopted as the
standard treatment following curative D2 gastric dissection.
DISCUSSION
Results from several phase II studies in advanced gastric cancer
were reported in the Japanese Guidelines for Treatment of Gastric
Cancer (2nd Edition) (Japanese Gastric Cancer Association, 2004),
with median response rates ranging from 41 to 78% and MSTs
ranging from 7 to 12.6 months, which were markedly higher than
the MST of 3.6 months observed for best supportive care. The
JCOG9912 trial compared the efficacy and toxicity of three
regimens: 5-FU, CPT-11þCDDP (CP), and S-1 (Boku et al,
2007). In this study, the MSTs were 9.0, 12.1, and 10.5 months for
5-FU, CP, and S-1, respectively, with S-1 demonstrating significant
non-inferiority to 5-FU, while CP did not show statistically
significant superiority to 5-FU. On the basis of these results, S-1
monotherapy was adopted as the standard cancer chemotherapy
regimen for inoperable and recurrent gastric cancer in Japan.
However, after the SPIRITS trial (Koizumi et al, 2008) revealed the
superiority of S-1þCDDP compared with S-1 alone, the preferred
chemotherapy regimen for chemo-naive advanced gastric cancer
patients in Japan is now considered to be S-1þCDDP.
After many years of controversy regarding the utility of
postoperative gastric cancer chemotherapy, the ACTS-GC study
has demonstrated the efficacy of S-1 monotherapy as adjuvant
treatment following D2 dissection of stage II/III gastric cancer.
However, there appears to be ethnic differences in the pharmaco-
kinetic profile of S-1. Chu et al (2004) have evaluated S-1 given
once daily for 28 days every 5 weeks for the determination of
maximum tolerated dose, pharmacokinetics, and anticancer
activity for non-Japanese patients. The maximum tolerated dose
was defined as the highest dose at which fewer than two of the first
six new patients experience dose-limiting toxicity. When 20
patients were treated with S-1 at three dose levels ranging from
50–70mgm
 2 per day, diarrhoea associated with abdominal
discomfort and cramping was the principal dose-limiting toxicity.
Nausea, vomiting, mucositis, fatigue, and cutaneous effects were
also observed, but were not dose-limiting; bone marrow suppres-
sion was also not dose-limiting. These results contradict those
observed in Japanese patients, who tend to develop dose-limiting
bone marrow toxicity prior to experiencing gastrointestinal
adverse events. This might be due to the different activity of
OPRT, which activates 5-FU in the bowel mucosa, in Japanese
patients. Patients with higher OPRT activity might be expected to
experience a higher incidence of gastrointestinal adverse effects
prior to bone marrow toxicity, even after similar Oxo dosing. On
the basis of this possible pharmacokinetic difference observed
between Japanese and non-Japanese patients, Chu et al (2004)
recommended S-1 50mgm
 2 per day administered once daily for
28 consecutive days every 5 weeks, which is significantly lower
than 80mgm
 2 per day for 4 weeks, the dose used in the ACTS-GC
study. This lower S-1 dose, which is used outside of Japan, was
used in the FLAGS study, a phase III advanced gastric cancer study
in which S-1 (50mgm
 2 per day, day 1–21)þDDP (75mgm
 2
per day, day 1) was compared to 5-FU (1000mgm
 2 per day, day
1–5)þDDP (100mgm
 2 per day, day 1), which is considered to
be the standard therapy for advanced gastric cancer. The results of
the FLAGS study will be reported in 2008.
S-1 is now considered to be a key drug for inoperable and
recurrent gastric cancer, as well as adjuvant cancer chemotherapy
after D2 gastrectomy in Japan. While combinations of S-1 with
DDP, CPT-11, and docetaxel will be confirmed by phase III studies,
how to best sequence these regimens following late recurrences
after S-1 adjuvant therapy remains unknown. While the commonly
used standard 5-FUþDDP regimen will be compared to S-
1þDDP in the FLAGS trial, these doublets should also be
compared to triplet regimens such as docetaxel, DDP, and 5-FU
(DCF) (Van Cutsem et al, 2006). In addition, recently introduced
molecularly targeted therapies, including monoclonal antibodies
and tyrosine kinase inhibitors, are excellent candidates for
combining with conventional antitumour agents, as has been
successfully done in colorectal cancer.
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